PU.1 affects proliferation of the human acute myeloid leukemia U937 cell line by directly regulating MEIS1

被引:6
|
作者
Zhou, Jing [1 ,2 ]
Zhang, Xiaofeng [3 ]
Wang, Yuhua [2 ,4 ]
Guan, Yinghui [5 ]
机构
[1] Chinese Acad Sci, Beijing Inst Genom, Lab Genome Variat & Precis Biomed, Beijing 100101, Peoples R China
[2] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA 02142 USA
[3] Univ Massachusetts, Dept Chem, Boston, MA 02125 USA
[4] Shanghai Jiao Tong Univ, Sch Med, Coll Stomatol, Shanghai Key Lab Stomatol,Dept Prosthodont,People, Shanghai 200011, Peoples R China
[5] Jilin Univ, Resp Dept, Branch 2, Hosp 1, Changchun 130021, Jilin, Peoples R China
基金
中国国家自然科学基金;
关键词
PU.1; MEIS1; leukemia; transcription; TRANSCRIPTION FACTOR PU.1; HEMATOPOIETIC PROGENITORS; COMMITMENT; EXPRESSION; MUTATIONS; TARGETS; HOXA9; FATE;
D O I
10.3892/ol.2015.3404
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The transcription factor PU.1 is a member of the ETS family, which is expressed in a wide variety of hematopoietic lineages. Accumulating evidence has indicated that PU.1 plays a key role in hematopoiesis, and reduced expression of PU.1 leads to the pathogenesis of human myeloid leukemia. As a multi-functional factor, PU.1 is also required for mixed lineage leukemia (MLL) stem cell potential and the development of MLL. However, the function of PU.1 in human non-MLL leukemia and its molecular mechanism remains poorly understood. In the present study, PU.1 siRNA was demonstrated to efficiently inhibit the transcription level of oncogene MEIS1 in the human acute myeloid non-MLL leukemia U937 cell line. In addition, PU.1, as a positive regulator of MEIS1, performed a crucial role in maintaining cell proliferation. Using electrophoretic mobility shift assay, chromatin immunoprecipitation analysis and luciferase reporter assay, previously unexplored evidence that PU.1 activated the MEIS1 promoter through a conserved binding motif in vitro and in vivo was further defined. Overall, the present study provides insight into the molecular mechanism of the contribution of PU.1 to the pathogenesis of non-MLL U937 cells, which is mediated by direct regulation of MEIS1 transcription. The present data reveal the possibility of developing an alternative therapy for non-MLL leukemia by targeting PU.1-mediated MEIS1 gene activation.
引用
收藏
页码:1912 / 1918
页数:7
相关论文
共 50 条
  • [41] Evaluation of the HOXA9 and MEIS1 genes as a potential biomarker in adult acute myeloid leukemia
    Abdelrahman, Amira M. N.
    Tolba, Fetnat Mahmoud
    Kamal, Howyda Mohamed
    Abdellateif, Mona S.
    Ahmed, Heba Abdelmoneim
    Hassan, Naglaa M.
    EGYPTIAN JOURNAL OF MEDICAL HUMAN GENETICS, 2023, 24 (01)
  • [42] Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60/VCR
    Liang, Rong
    Huang, Gao-sheng
    Wang, Zhe
    Chen, Xie-qun
    Bai, Qin-xian
    Zhang, Yong-qing
    Dong, Bao-xia
    Wang, Wen-qing
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 87 (02) : 152 - 166
  • [43] Effects of human bone marrow stromal cell line (HFCL) on the proliferation, differentiation and apoptosis of acute myeloid leukemia cell lines U937, HL-60 and HL-60/VCR
    Rong Liang
    Gao-sheng Huang
    Zhe Wang
    Xie-qun Chen
    Qin-xian Bai
    Yong-qing Zhang
    Bao-xia Dong
    Wen-qing Wang
    International Journal of Hematology, 2008, 87 : 152 - 166
  • [44] PU.1 Is a Downstream Target of C/EBPα in Normal Hematopoiesis and Acute Myeloid Leukemia
    Bach, Christian
    Staber, Philipp B.
    Ye, Min
    Zhang, Pu
    Friedman, Alan D.
    Delwel, Ruud
    Tenen, Daniel G.
    BLOOD, 2011, 118 (21) : 595 - 595
  • [45] The Transcription Factor PU.1 Controls a Reversible Differentiation Program in Acute Myeloid Leukemia
    McKenzie, Mark D.
    Ghisi, Margherita
    Cimmino, Luisa
    Erlichster, Michael
    Oxley, Ethan P.
    Liu, Cynthia
    Witkowski, Matthew T.
    Liu, Grace
    Dakic, Aleksandar
    Simankowicz, Emilia
    DiRago, Ladina
    Metcalf, Donald
    Nutt, Stephen L.
    Wall, Meaghan
    Ritchie, Matthew E.
    Zuber, Johannes
    Dickins, Ross A.
    BLOOD, 2016, 128 (22)
  • [46] Apoptosis, necrosis and cell proliferation-inhibition by cyclosporine A in U937 cells (a human monocytic cell line)
    Roy, MK
    Takenaka, M
    Kobori, M
    Nakahara, K
    Isobe, S
    Tsushida, T
    PHARMACOLOGICAL RESEARCH, 2006, 53 (03) : 293 - 302
  • [47] Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia
    Schneider, Edith
    Staffas, Anna
    Roehner, Linda
    Malmberg, Erik D.
    Ashouri, Arghavan
    Krowiorz, Kathrin
    Pochert, Nicole
    Miller, Christina
    Wei, Stella Yuan
    Arabanian, Laleh
    Buske, Christian
    Doehner, Hartmut
    Bullinger, Lars
    Fogelstrand, Linda
    Heuser, Michael
    Doehner, Konstanze
    Xiang, Ping
    Ruschmann, Jens
    Petriv, Oleh I.
    Heravi-Moussavi, Alireza
    Hansen, Carl L.
    Hirst, Martin
    Humphries, R. Keith
    Rouhi, Arefeh
    Palmqvist, Lars
    Kuchenbauer, Florian
    HAEMATOLOGICA, 2018, 103 (02) : 246 - 255
  • [48] DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
    Ferreira, H. J.
    Heyn, H.
    Vizoso, M.
    Moutinho, C.
    Vidal, E.
    Gomez, A.
    Martinez-Cardus, A.
    Simo-Riudalbas, L.
    Moran, S.
    Jost, E.
    Esteller, M.
    ONCOGENE, 2016, 35 (23) : 3079 - 3082
  • [49] DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia
    H J Ferreira
    H Heyn
    M Vizoso
    C Moutinho
    E Vidal
    A Gomez
    A Martínez-Cardús
    L Simó-Riudalbas
    S Moran
    E Jost
    M Esteller
    Oncogene, 2016, 35 : 3079 - 3082
  • [50] A novel engineered dominant silencing form of MEIS1 suppresses HOX-mediated acute myeloid leukemia
    Argiropoulos, B.
    Palmqvist, L.
    Yung, E.
    Goh, S.
    Featherstone, M.
    Humphries, K.
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (09) : 27 - 28